System with integral locking mechanism
    1.
    发明授权
    System with integral locking mechanism 有权
    具有整体锁定机构的系统

    公开(公告)号:US08591555B2

    公开(公告)日:2013-11-26

    申请号:US12551152

    申请日:2009-08-31

    IPC分类号: A61B17/80

    摘要: A system for affixing at least two portions of bone is provided. The system has a first end cap, a second end cap, and a linking member extending between the first end cap and the second end cap. The first end cap has at least one leg configured to connect the linking member to the first end cap and configured to retain the connection. The system provides an integral locking system mechanism that does not require an additional locking element.

    摘要翻译: 提供了用于固定至少两部分骨的系统。 该系统具有第一端盖,第二端盖和在第一端盖和第二端盖之间延伸的连接构件。 第一端盖具有至少一个支腿,其构造成将连接构件连接到第一端盖并且构造成保持连接。 该系统提供了不需要额外的锁定元件的整体锁定系统机构。

    IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
    6.
    发明申请
    IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY 有权
    调节HSP90活性的咪唑化合物

    公开(公告)号:US20140094436A1

    公开(公告)日:2014-04-03

    申请号:US14103420

    申请日:2013-12-11

    摘要: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.

    摘要翻译: 式(I)化合物,包含式(I)化合物的药物组合物和抑制细胞中Hsp90的方法,治疗或预防哺乳动物中的增殖病症并治疗哺乳动物的癌症,其包括给予式(I)化合物至 患者或细胞。 变量R5是任选取代的杂芳基; 任选取代的6至14元芳基; 任选在任何可取代的氮或碳原子上取代的双环9元杂环; 或本文定义的取代基R18。 环A是除了R3之外任选进一步被一个或多个取代基取代的芳基或杂芳基。 取代基R 3在本文中定义。